Cell Therapy for Refractory Angina: A Reappraisal.

about

Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133 cells in ischemic refractory cardiomyopathy trial (RECARDIO)

P2860

Q58741622-6C52854B-5D44-48E3-953F-CAD09DCEDA80

P2860

Cell Therapy for Refractory Angina: A Reappraisal.

Item

http://www.wikidata.org/entity/Q48155875

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Cell Therapy for Refractory Angina: A Reappraisal.

@en

Cell Therapy for Refractory Angina: A Reappraisal.

@nl

type

Item

label

Cell Therapy for Refractory Angina: A Reappraisal.

@en

Cell Therapy for Refractory Angina: A Reappraisal.

@nl

prefLabel

Cell Therapy for Refractory Angina: A Reappraisal.

@en

Cell Therapy for Refractory Angina: A Reappraisal.

@nl

P1476

Cell Therapy for Refractory Angina: A Reappraisal

@en

P2093

Felice Achilli

http://www.w3.org/2001/XMLSchema#string

Laura Cavallotti

http://www.w3.org/2001/XMLSchema#string

Paolo Scacciatella

http://www.w3.org/2001/XMLSchema#string

Stefano Righetti

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy.

Impact of Cell Therapy on Myocardial Perfusion and Cardiovascular Outcomes in Patients With Angina Refractory to Medical Therapy: A Systematic Review and Meta-Analysis.

Transmyocardial laser revascularization combined with intramyocardial endothelial progenitor cell transplantation in patients with intractable ischemic heart disease ineligible for conventional revascularization: preliminary results in a highly sele

Intramyocardial injection of bone marrow mononuclear cells in chronic myocardial ischemia patients after previous placebo injection improves myocardial perfusion and anginal symptoms: an intra-patient comparison.

The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina.

Bone Marrow Stem Cell Treatment for Ischemic Heart Disease in Patients with No Option of Revascularization: A Systematic Review and Meta-Analysis.

Fatality, morbidity and quality of life in patients with refractory angina pectoris.

Predictors of long-term clinical endpoints in patients with refractory angina

Intramyocardial, autologous CD34+ cell therapy for refractory angina.

Safety and feasibility of percutaneous retrograde coronary sinus delivery of autologous bone marrow mononuclear cell transplantation in patients with chronic refractory angina.

P304

5648690

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2017/5648690

http://www.w3.org/2001/XMLSchema#string

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29375624

http://www.w3.org/2001/XMLSchema#string

P932

5742462

http://www.w3.org/2001/XMLSchema#string

Cell Therapy for Refractory Angina: A Reappraisal.

about

P2860

P2860

Cell Therapy for Refractory Angina: A Reappraisal.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932